JP2013504536A5 - - Google Patents

Download PDF

Info

Publication number
JP2013504536A5
JP2013504536A5 JP2012528347A JP2012528347A JP2013504536A5 JP 2013504536 A5 JP2013504536 A5 JP 2013504536A5 JP 2012528347 A JP2012528347 A JP 2012528347A JP 2012528347 A JP2012528347 A JP 2012528347A JP 2013504536 A5 JP2013504536 A5 JP 2013504536A5
Authority
JP
Japan
Prior art keywords
alkylene
alkyl
substituted
unsubstituted
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012528347A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013504536A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2010/063169 external-priority patent/WO2011029842A1/en
Publication of JP2013504536A publication Critical patent/JP2013504536A/ja
Publication of JP2013504536A5 publication Critical patent/JP2013504536A5/ja
Pending legal-status Critical Current

Links

JP2012528347A 2009-09-10 2010-09-08 癌の処置のためのbcl−2ファミリータンパク質阻害剤としてのスルホンアミド類 Pending JP2013504536A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24125109P 2009-09-10 2009-09-10
US61/241,251 2009-09-10
PCT/EP2010/063169 WO2011029842A1 (en) 2009-09-10 2010-09-08 Sulfonamides as inhibitors of bcl-2 family proteins for the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2013504536A JP2013504536A (ja) 2013-02-07
JP2013504536A5 true JP2013504536A5 (enExample) 2013-10-17

Family

ID=43016684

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012528347A Pending JP2013504536A (ja) 2009-09-10 2010-09-08 癌の処置のためのbcl−2ファミリータンパク質阻害剤としてのスルホンアミド類

Country Status (12)

Country Link
US (1) US8809352B2 (enExample)
EP (1) EP2475661B1 (enExample)
JP (1) JP2013504536A (enExample)
KR (1) KR20120078715A (enExample)
CN (1) CN102498111A (enExample)
AU (1) AU2010294292B2 (enExample)
BR (1) BR112012005343A2 (enExample)
CA (1) CA2772989A1 (enExample)
EA (1) EA020586B1 (enExample)
ES (1) ES2443845T3 (enExample)
MX (1) MX2012003007A (enExample)
WO (1) WO2011029842A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG192126A1 (en) * 2011-01-25 2013-09-30 Univ Michigan Bcl-2/bcl-xl inhibitors and therapeutic methods using the same
JP2015503515A (ja) 2011-12-23 2015-02-02 ノバルティス アーゲー Bcl2と結合相手の相互作用を阻害するための化合物および組成物
EA201491264A1 (ru) 2011-12-23 2014-11-28 Новартис Аг Соединения для ингибирования взаимодействия bcl-2 с партнерами по связыванию
LT6064B (lt) 2012-10-15 2014-08-25 Vilniaus Universitetas Fluorinti benzensulfonamidai kaip karboanhidrazės inhibitoriai
SG10201704327RA (en) 2013-10-14 2017-06-29 Eisai R&D Man Co Ltd Selectively substituted quinoline compounds
MX363708B (es) 2013-10-14 2019-03-29 Eisai R&D Man Co Ltd Compuestos de quinolina selectivamente sustituidos.
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
CN108349924A (zh) 2015-08-12 2018-07-31 纪念斯隆凯特林癌症中心 苯磺酰氨基-苯并呋喃衍生物及其用途
AU2017206731A1 (en) * 2016-01-11 2018-08-02 Merrimack Pharmaceuticals, Inc. Inhibiting B-cell lymphoma 2 (Bcl-2) and related proteins
US10570119B2 (en) 2016-01-11 2020-02-25 Merrimack Pharmaceuticals, Inc. Inhibiting ataxia telangiectasia and Rad3-related protein (ATR)
HUE071493T2 (hu) 2018-04-29 2025-09-28 Beigene Switzerland Gmbh Bcl-2 inhibitorok
US11198699B2 (en) 2019-04-02 2021-12-14 Aligos Therapeutics, Inc. Compounds targeting PRMT5
BR112022019525A2 (pt) 2020-04-15 2023-11-14 Beigene Ltd Composto, composição farmacêutica e método para tratar doenças apoptóticas desreguladas
EP4538273A1 (en) * 2022-06-10 2025-04-16 Hitgen Inc. Compound and use thereof in preparation of bcl-xl inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE372330T1 (de) * 2002-03-21 2007-09-15 Abbott Lab N-sulfonylurea-apoptosis-förderer
US20040157836A1 (en) * 2002-10-08 2004-08-12 Comess Kenneth M. Sulfonamides having antiangiogenic and anticancer activity
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
CN101039662A (zh) * 2004-08-20 2007-09-19 密执安州立大学董事会 抗-细胞凋亡bcl-2家族成员的小分子抑制剂及其应用
CN101535280B (zh) * 2006-11-15 2012-06-27 健泰科生物技术公司 芳基磺酰胺化合物
FR2912145B1 (fr) * 2007-02-02 2009-03-06 Servier Lab Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Similar Documents

Publication Publication Date Title
JP2013504536A5 (enExample)
JP2013209405A5 (enExample)
RU2015118647A (ru) Аминопиримидиновые соединения в качестве ингибиторов содержащих т790м мутантных egfr
JP2019510832A5 (enExample)
JP2016040288A5 (enExample)
JP2017528498A5 (enExample)
JP2016506962A5 (enExample)
JP2012041349A5 (enExample)
JP2014518882A5 (enExample)
JP2015501833A5 (enExample)
JP2016506961A5 (enExample)
JP2013510120A5 (enExample)
JP2016506960A5 (enExample)
JP2009543867A5 (enExample)
JP2013531031A5 (enExample)
JP2015512931A5 (enExample)
JP2015517566A5 (enExample)
JP2015504067A5 (enExample)
JP2019501195A5 (ja) 腫瘍を処置するための抗egfr組み合わせ
RU2016134751A (ru) Соединения
RU2018106453A (ru) Соединения
JP2015520143A5 (enExample)
JP2007502820A5 (enExample)
JP2017517538A5 (enExample)
JP2019501197A5 (ja) 腫瘍を処置するための抗her2組み合わせ